---
title: >-
  Real-World Effectiveness of Cannabidiol on Antiseizure Medication Cycling,
  Polypharmacy, and Healthcare Resource Utilization: A US Claims Analysis.
description: >-
  Explore this publication on real-world evidence: Real-World Effectiveness of
  Cannabidiol on Antiseizure Medication Cycling, Polypharmacy, and Healthcare…
date: '2026-01-01'
category: Publications
tags:
  - Jazz Pharmaceuticals
  - Poster Presentation
  - Pharma Partner
  - Approval & Commercialization
  - 'No'
  - Methods/Pharmacoepi
  - R&D
canonical_url: >-
  https://www.headwaterscience.com/resources/publications/ind-jazz-pharmaceuticals/real-world-effectiveness-of-cannabidiol-on-antiseizure/
source: Headwater Science
license: © 2026 Headwater Science. All rights reserved.
slug: real-world-effectiveness-of-cannabidiol-on-antiseizure
id: 6ovb8dlStrqvXe5QakbAN7
contentType: article
---

## Challenge

Updated or extended 2026 analysis of CBD effectiveness on ASM cycling, polypharmacy, and HCRU in epilepsy patients, building on the 2025 study (Row 105). Jazz Pharmaceuticals funded.

## Solution

Target RWE researchers provided updated or extended real-world effectiveness analyses of CBD on antiseizure medication cycling, polypharmacy burden, and healthcare resource utilization, funded by Jazz Pharmaceuticals.

## Impact

Updated post-market CBD effectiveness evidence extends the duration and scope of the real-world evidence base for Jazz Pharmaceuticals, supporting ongoing label messaging, formulary negotiations, and prescriber education programs.

## Use Cases / Links

Updated CBD post-market effectiveness evidence for ASM cycling and polypharmacy for Jazz Pharmaceuticals, Extended real-world cannabidiol effectiveness data for treatment-resistant epilepsy payer and label strategy